Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease

Expert Review of Clinical Immunology

Volumn 6, Issue 4, 2010, Pages 621-631

  Bewtra, Meenakshi ^a   Lewis, James D ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

hepatosplenic T cell lymphoma; immunosuppression; inflammatory bowel disease; lymphoma; non Hodgkins lymphoma

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; BETA INTERFERON; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

AGGRESSIVENESS; B CELL LYMPHOMA; CLINICAL TRIAL; CROHN DISEASE; DRUG WITHDRAWAL; ENTERITIS; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; REVIEW; RISK; RISK BENEFIT ANALYSIS; T CELL LYMPHOMA;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; RISK ASSESSMENT; RISK FACTORS;

EID: 77954403026     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.36     Document Type: Review

References (107)

1. Engels EA, Biggar RJ, Hall HI et al. Cancer risk in people infected with human immunodefciency virus in the United States. Int. J. Cancer 123(1), 187-194 (2008).
2. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune defciency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defc. Syndr. 32(5), 527-533 (2003). (Pubitemid 36423125)
3. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl Cancer Inst. 99(12), 962-972 (2007).
4. Kamel OW, van de Rijn M, Weiss LM et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med. 328(18), 1317-1321 (1993).
5. Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol. 133(1), 173-192 (1988).
6. Paul C, Le Tourneau A, Cayuela JM et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch. Dermatol. 133(7), 867-871 (1997). (Pubitemid 27337547)
7. Pietersma F, Piriou E, van Baarle D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk. Lymphoma 49(6), 1028-1041 (2008). (Pubitemid 351943248)
8. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol. Dial. Transplant. 22(Suppl. 1), i4-i10 (2007). (Pubitemid 47073738)
9. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 80(2 Suppl.), S254-S264 (2005).
10. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum. 39(2), 325-329 (1996). (Pubitemid 26065275)
11. Liote F, Pertuiset E, Cochand-Priollet B et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J. Rheumatol. 22(6), 1174-1178 (1995).
12. Hoshida Y, Xu JX, Fujita S et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J. Rheumatol. 34(2), 322-331 (2007). (Pubitemid 46255749)
13. Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J. Clin. Oncol. 14(6), 1943-1949 (1996). (Pubitemid 26185470)
14. Viraben R, Brousse P, Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br. J. Dermatol. 135(1), 116-118 (1996). (Pubitemid 26225129)
15. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351(9103), 623-628 (1998). (Pubitemid 28098444)
16. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4(2), 222-230 (2004). (Pubitemid 38248525)
17. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 67(8), 1167-1198 (2007). (Pubitemid 46871026)
18. Guba M, Graeb C, Jauch KW, Geissler EK. Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77(12), 1777-1782 (2004). (Pubitemid 38822196)
19. Herman M, Weinstein T, Korzets A et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J. Lab. Clin. Med. 137(1), 14-20 (2001). (Pubitemid 32100171)
20. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1(8377), 583-587 (1984). (Pubitemid 14156511)
21. Zijlmans JM, van Rijthoven AW, Kluin PM, Jiwa NM, Dijkmans BA, Kluin-Nelemans JC. Epstein-Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. N. Engl. J. Med. 326(20), 1363 (1992).
22. Watabe H, Soma Y, Obara W et al. Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm. Venereol. 86(2), 184-185 (2006). (Pubitemid 44020197)
23. Lelievre JD, Sacre K, Adle-Biassette H, Molinier-Frenkel V, Gaulard P, Papo T. Epstein-Barr virus-associated lymphoproliferative disease after longstanding cyclosporine therapy for psoriasis: a case of spontaneous regression. J. Am. Acad. Dermatol. 52(2 Suppl. 1), 24-27 (2005). (Pubitemid 40164757)
24. + large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 206(4), 330-333 (2003). (Pubitemid 36677019)
25. + T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infiximab. Br. J. Dermatol. 149(1), 170-173 (2003). (Pubitemid 36966529)
26. Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J. Autoimmun. 2(5), 723-731 (1989).
27. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specifc immunosuppressive drug or by the transplantation per se? Transplantation 76(6), 984-988 (2003). (Pubitemid 37186032)
28. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol. 120(2), 211-216 (2003). (Pubitemid 36513069)
29. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol. 114(3), 587-590 (2000). (Pubitemid 30415349)
30. Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin's lymphoma in infammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47(4), 514-519 (2000).
31. Shibahara T, Miyazaki K, Sato D et al. Rectal malignant lymphoma complicating ulcerative colitis treated with long-term cyclosporine A. J. Gastroenterol. Hepatol. 21(1 Pt 2), 336-338 (2006).
32. Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for infammatory bowel disease. Clin. Gastroenterol. Hepatol. 4(8), 1030-1034 (2006). (Pubitemid 44118850)
33. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J. Rheumatol. 18(11), 1741-1743 (1991).
34. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J. Rheumatol. 19(9), 1462-1465 (1992).
35. Thomason RW, Craig FE, Banks PM, Sears DL, Myerson GE, Gulley ML. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod. Pathol. 9(3), 261-266 (1996). (Pubitemid 26126552)
36. Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB. Methotrexate-induced pulmonary lymphoma. Chest 123(6), 2150-2153 (2003).
37. Suzuki M, Hirano S, Ito H et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology 12(5), 774-776 (2007). (Pubitemid 47414893)
38. Khopkar U, Bhor U. Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy. Indian J. Dermatol. Venereol. Leprol. 74(4), 379-382 (2008).
39. Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst. 85(4), 307-311 (1993). (Pubitemid 23068804)
40. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am. J. Med. 78(1A), 29-32 (1985). (Pubitemid 15167362)
41. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J. Chronic Dis. 31(11), 691-696 (1978). (Pubitemid 12151677)
42. Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am. J. Med. 78(1A), 15-21 (1985). (Pubitemid 15167360)
43. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann. Rheum. Dis. 47(12), 988-992 (1988). (Pubitemid 19005407)
44. Symmons DP. Neoplasms of the immune system in rheumatoid arthritis. Am. J. Med. 78(1A), 22-28 (1985). (Pubitemid 15167361)
45. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50(6), 1740-1751 (2004). (Pubitemid 38725085)
46. Santana V, Rose NR. Neoplastic lymphoproliferation in autoimmune disease: an updated review. Clin. Immunol. Immunopathol. 63(3), 205-213 (1992).
47. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 50(5), 869-872 (1982). (Pubitemid 12047118)
48. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch. Dermatol. 142(9), 1132-1135 (2006).
49. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch. Intern. Med. 168(4), 378-381 (2008). (Pubitemid 351347129)
50. Buchbinder R, Barber M, Heuzenroeder L et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 59(6), 794-799 (2008). (Pubitemid 351847561)
51. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis. 68(7), 1100-1104 (2009).
52. + T lymphocytes. J. Clin. Invest. 111(8), 1133-1145 (2003). (Pubitemid 36519931)
53. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of infammatory bowel disease: short-and long-term toxicity. Ann. Intern. Med. 111(8), 641-649 (1989). (Pubitemid 19259182)
54. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in infammatory bowel disease. Lancet 343(8908), 1249-1252 (1994). (Pubitemid 24158045)
55. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol. 91(9), 1711-1714 (1996). (Pubitemid 126733996)
56. Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347(8996), 215-219 (1996). (Pubitemid 26035245)
57. Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of infammatory bowel disease with 6-mercaptopurine. Am. J. Gastroenterol. 94(11), 3248-3253 (1999).
58. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of infammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther. 16(7), 1225-1232 (2002).
59. Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of infammatory bowel disease. J. Clin. Gastroenterol. 39(1), 21-26 (2005).
60. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Infammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121(5), 1080-1087 (2001). (Pubitemid 33022087)
61. Armstrong RG, West J, Card TR. Risk of cancer in infammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am. J. Gastroenterol. (2010) (Epub ahead of print).
62. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for infammatory bowel disease: a prospective observational cohort study. Lancet 374(9701), 1617-1625 (2009).
63. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among infammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121-1125 (2005). (Pubitemid 41025906)
64. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in infammatory bowel disease. Ann. Pharmacother. 41(1), 21-28 (2007). (Pubitemid 46145952)
65. Dayharsh GA, Loftus EV Jr, Sandborn WJ et al. Epstein-Barr virus-positive lymphoma in patients with infammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122(1), 72-77 (2002).
66. Bewtra M, Lichtenstein GR. Infiximab use in Crohn's disease. Expert Opin. Biol. Ther. 5(4), 589-599 (2005).
67. Cohen RD, Tsang JF, Hanauer SB. Infiximab in Crohn's disease: frst anniversary clinical experience. Am. J. Gastroenterol. 95(12), 3469-3477 (2000).
68. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infiximab for Crohn's disease in clinical practice at the Mayo Clinic: the frst 100 patients. Am. J. Gastroenterol. 96(3), 722-729 (2001). (Pubitemid 32240722)
69. Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infiximab in infammatory bowel disease patients. A retrospective cohort study in 10 0 patients of a German University Hospital. Digestion 70(1), 3-9 (2004).
70. Wenzl HH, Reinisch W, Jahnel J et al Austrian infiximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur. J. Gastroenterol Hepatol. 16(8), 767-773 (2004). (Pubitemid 39062568)
71. Sands BE, Anderson FH, Bernstein CN et al. Infiximab maintenance therapy for fstulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004). (Pubitemid 38252535)
72. Rutgeerts P, Sandborn WJ, Feagan BG et al Infiximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). (Pubitemid 41770166)
73. Caspersen S, Elkjaer M, Riis L et al. Infiximab for infammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol Hepatol. 6(11), 1212-1217; quiz 1176 (2008).
74. Lichtenstein GR, Cohen R, Feagan BG et al. Safety of infiximab and other Crohn's disease therapies: TREAT™ registry data with 24,575 patient-years of follow-up. Am. J. Gastroenterol. 103(S1), (2008).
75. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
76. Ljung T, Karlen P, Schmidt D et al. Infiximab in infammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53(6), 849-853 (2004). (Pubitemid 38662135)
77. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profle of infiximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126(1), 19-31 (2004).
78. Lees CW, Ali AI, Thompson AI et al. The safety profle of anti-tumour necrosis factor therapy in infammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther. 29(3), 286-297 (2009).
79. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46(12), 3151-3158 (2002).
80. FDA Board Document. Update on the TNF-a blocking agents; 2003 (2009).
81. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-a antagonists. Drug Saf. 27(5), 307-324 (2004). (Pubitemid 38530461)
82. Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-a inhibitors in the treatment of rheumatoid arthritis. Curr. Rheumatol. Rep. 5(4), 270-277 (2003).
83. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor a blockers etanercept, infiximab and adalimumab. J. Dermatolog. Treat. 15(5), 280-294 (2004). (Pubitemid 39423287)
84. Schiff MH, Burmester GR, Kent JD et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65(7), 889-894 (2006).
85. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130(2), 323-333 (2006). (Pubitemid 43202032)
86. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1), 52-65 (2007). (Pubitemid 46108762)
87. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007). (Pubitemid 47080387)
88. Rosh JR, Lerer T, Markowitz J et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am. J. Gastroenterol. 104(12), 3042-3049 (2009).
89. ® Injection Prescribing Information and Medication Guide. Abbot Laboratories, IL, USA (2009).
90. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129(3), 807-818 (2005). (Pubitemid 41242673)
91. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357(3), 239-250 (2007). (Pubitemid 47080388)
92. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Effcacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008). (Pubitemid 351783447)
93. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7(8), 874-881 (2009).
94. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132(5), 1672-1683 (2007). (Pubitemid 46695722)
95. Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol. 66(3), 403-406 (2009).
96. Khan WA, Yu L, Eisenbrey AB et al. Hepatosplenic g/d T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am. J. Clin. Pathol. 116(1), 41-50 (2001). (Pubitemid 32601125)
97. Ochenrider MG, Patterson DJ, Aboulafa DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin. Lymphoma Myeloma Leuk. 10(2), 144-148 (2010).
98. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infiximab use in young patients treated for infammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007). (Pubitemid 46175082)
99. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. 40(2), 220-222 (2005). (Pubitemid 40269746)
100. Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infiximab therapy Leuk. Lymphoma 48(7), 1410-1413 (2007). (Pubitemid 47079370)
101. Humphreys MR, Cino M, Quirt I, Barth D, Kukreti V. Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-a. Leuk. Lymphoma 49(7), 1420-1423 (2008). (Pubitemid 352015810)
102. Lewis JD, Gelfand JM, Troxel AB et al. Immunosuppressant medications and mortality in infammatory bowel disease. Am. J. Gastroenterol. 103(6), 1428-1435; quiz 1436 (2008).
103. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefts of infiximab for the treatment of Crohn's disease. Clin. Gastroenterol. Hepatol. 4(8), 1017-1024 (2006). (Pubitemid 44137437)
104. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefts outweigh the risk of lymphoma. Gastroenterology 118(6), 1018-1024 (2000).
105. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with infammatory bowel disease. Gastroenterology 134(4), 929-936 (2008). (Pubitemid 351451967)
106. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infiximab maintenance: a randomized trial. Gastroenterology 134(7), 1861-1868 (2008). (Pubitemid 351790744)
107. Sandborn WJ, Rutgeerts PJ, Reinisch W et al. One year data from the SONIC study: a randomized, double-blind trial comparing infiximab and infiximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Presented at: Digestive Disease Week 2009. 30 May-4 June 2009, Chicago, IL, USA (Abstract 751f). 667